Ukraine United States of America Donald Trump Iran Russia Andy Burnham Canada Samsung Electronics Strait of Hormuz Tehran G7 European Union OpenAI
Keio University confirms long-term safety of iPS spinal cord therapy
science
innovative
ground breaking breakthrough

Keio University confirms long-term safety of iPS spinal cord therapy

21
(Update: )
island country in East Asia
  • Researchers at Keio University confirmed the long-term safety of iPS spinal cord therapy after transplanting neural progenitor cells into patients.
  • The study involved four patients and showed no major safety concerns or tumor formation even two to four years post-surgery.
  • The findings highlight the potential of iPS cell therapy, but further clinical trials are necessary to verify its effectiveness.
Share opinion
2

Story

“

In Japan, researchers at Keio University have confirmed the long-term safety of a groundbreaking treatment involving induced pluripotent stem (iPS) cells for spinal cord injuries. Between 2020 and 2025, the team, led by Professor Hideyuki Okano, conducted a clinical study where approximately 2 million iPS cell-derived neural progenitor cells were transplanted into four patients who were in the subacute stage of spinal cord injury. This treatment was administered within four weeks of their injuries, marking a significant advancement in regenerative medicine. The results of the one-year postoperative follow-ups indicated no major safety concerns, and some patients even showed improvements in physical function. Notably, two patients regained some muscle control despite having completely lost motor function prior to the treatment. The latest findings, published in the international medical journal Nature Medicine, revealed that no major safety issues, including tumor formation, were observed in any of the four individuals even two to four years post-surgery. However, the researchers emphasized that the effectiveness of the treatment must be verified through larger clinical trials due to the small sample size of the study. In a related development, the Central Social Insurance Medical Council in Japan approved public health insurance coverage for RiHeart, a cardiac muscle cell sheet derived from iPS cells, effective September 1. This marks the second instance of insurance coverage approval for an iPS cell-derived regenerative medicine product in Japan. RiHeart, developed by the startup Cuorips, is designed to restore heart function in patients with severe heart failure by using myocardial cells processed into sheets. The product is expected to be available for sale in Japan this autumn, with a domestic price set at ¥53.2 million ($326,400). The high-cost medical care benefit system will significantly reduce out-of-pocket expenses for patients undergoing this treatment. The health ministry had previously granted conditional approval for RiHeart and another iPS cell-based product, Amchepry, for patients with Parkinson's disease, with full-scale approvals pending further data collection over the next seven years.

Context

“

Induced pluripotent stem cells (iPSCs) have emerged as a promising avenue for the treatment of spinal cord injuries (SCIs), offering potential for regeneration and repair of damaged neural tissues. iPSCs are derived from somatic cells and possess the ability to differentiate into various cell types, including neurons and glial cells, which are crucial for spinal cord function. The application of iPSCs in SCI treatment is particularly appealing due to their ability to bypass ethical concerns associated with embryonic stem cells and their potential for autologous transplantation, reducing the risk of immune rejection. Recent advancements in reprogramming techniques have enhanced the efficiency and safety of generating iPSCs, paving the way for their clinical application in regenerative medicine. Research has demonstrated that iPSCs can be differentiated into neural progenitor cells (NPCs) and subsequently into mature neurons and oligodendrocytes, which are essential for restoring neuronal connections and myelination in the injured spinal cord. Preclinical studies using animal models of SCI have shown that transplantation of iPSC-derived NPCs can lead to significant functional recovery, improved locomotor activity, and enhanced tissue repair. These findings underscore the potential of iPSCs to not only replace lost cells but also to create a supportive microenvironment that promotes endogenous repair mechanisms. Furthermore, the ability to genetically modify iPSCs allows for the introduction of neuroprotective factors or genes that can enhance survival and integration of transplanted cells. Despite the promising results, several challenges remain before iPSC-based therapies can be widely implemented in clinical settings. One major concern is the risk of tumorigenesis associated with the uncontrolled proliferation of transplanted iPSCs. To mitigate this risk, researchers are exploring strategies such as using small molecules to promote differentiation before transplantation or employing suicide genes that can selectively eliminate transplanted cells if necessary. Additionally, the development of standardized protocols for the generation and differentiation of iPSCs is crucial to ensure reproducibility and safety in clinical applications. Regulatory hurdles and the need for extensive preclinical and clinical trials also pose significant barriers to the translation of iPSC therapies into routine clinical practice. In conclusion, induced pluripotent stem cells represent a revolutionary approach to treating spinal cord injuries, with the potential to restore function and improve the quality of life for affected individuals. Ongoing research is essential to address the challenges associated with their use, including safety, efficacy, and ethical considerations. As our understanding of iPSC biology and their interactions within the spinal cord microenvironment continues to evolve, it is likely that we will see significant advancements in the development of iPSC-based therapies for spinal cord injury in the coming years. The integration of iPSC technology into clinical practice holds the promise of transforming the landscape of SCI treatment, offering hope for recovery where traditional therapies have failed.